Dr. Curigliano Discusses Immunotherapy Trials in Breast Cancer

Giuseppe Curigliano, MD, PhD
Published: Wednesday, May 31, 2017



Giuseppe Curigliano, MD, PhD, head of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, discusses immunotherapy trials in triple-negative breast cancer (TNBC).

The biggest challenge facing immunotherapy in TNBC is proving that it works, says Curigliano.

The IMpassion130 trial is a prospective randomized trial that is comparing nab-paclitaxel (Abraxane) alone versus nab-paclitaxel plus atezolizumab (Tecentriq). It is currently ongoing.

Curigliano adds that data from neoadjuvant trials will be very important, as they may demonstrate that the addition of an immune checkpoint inhibitor increases pathologic complete response in patients with metastatic disease.
 


Giuseppe Curigliano, MD, PhD, head of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, discusses immunotherapy trials in triple-negative breast cancer (TNBC).

The biggest challenge facing immunotherapy in TNBC is proving that it works, says Curigliano.

The IMpassion130 trial is a prospective randomized trial that is comparing nab-paclitaxel (Abraxane) alone versus nab-paclitaxel plus atezolizumab (Tecentriq). It is currently ongoing.

Curigliano adds that data from neoadjuvant trials will be very important, as they may demonstrate that the addition of an immune checkpoint inhibitor increases pathologic complete response in patients with metastatic disease.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x